[Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention]
- PMID: 22384544
[Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention]
Abstract
Objective: To study the effects Xuezhikang (XZK) at different doses on inflammatory factors and blood lipids of patients suffering from acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) and to discuss their safety.
Methods: Eighty ACS in patients receiving selective PCI treatment were randomly assigned to two groups, 40 cases in the normal dose group and 40 cases in the large dose XZK group. Besides routine therapy, all patients took XZK at the daily dose of 1.2 and 0. 6 g, twice daily. They started XZK from the very day of PCI operation. The therapeutic course for all was more than 8 weeks. The levels of high sensitivity C reactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) were detected in the two groups 1 week, 4 and 8 weeks after operation. The levels of TC, TG, HDL-C, LDL-C, changes of liver and renal functions were observed. The correlation between blood lipids and inflammatory factors were analyzed. The adverse reaction was recorded.
Results: Compared with before medication, the serum levels of hs-CRP and MMP-9 decreased in the two groups 1 week, 4 and 8 weeks after operation, with statistical difference shown in the levels at the 8th week (P < 0.05). The decrease was more obvious in the large dose XZK group (P < 0.05). The LDL-C level obviously decreased in the two groups 4 and 8 weeks after operation (P < 0.05). The decrease was more obvious in the large dose XZK group at the 8th week (P < 0.05). The levels of hs-CRP and MMP-9 were positively correlated with the decrease degree of LDL-C in the large dose XZK group at the 8th week (r = 0.828, 0.922, P < 0.05). There was no significant difference in the occurrence of adverse reaction, hepatic or renal functions between the two groups.
Conclusions: XZK could lower the serum levels of hs-CRP, MMP-9, and LDL-C. More obvious effects were obtained in the large dose XZK group. The decrease degree of inflammatory factors was correlated with the decrease extent of blood lipids.
Similar articles
-
[Effects of Xuezhikang on serum levels of high sensitive-C reactive protein, matrix metalloproteinase-9 and lipoprotein in patients with acute coronary syndrome].Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Mar;26(3):221-3. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006. PMID: 16613266 Chinese.
-
Effects of withdrawal of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with coronary artery disease.Cardiovasc Drugs Ther. 2006 Jun;20(3):185-91. doi: 10.1007/s10557-006-7947-x. Cardiovasc Drugs Ther. 2006. PMID: 16775668 Clinical Trial.
-
[Effects of Guizhi Fuling Decoction on YKL-40 and hs-CRP of patients with non-ST segment elevation acute coronary syndrome].Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Feb;33(2):186-90. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013. PMID: 23646472 Clinical Trial. Chinese.
-
[Effect of triangle drugs as ginseng, Trichosanthes kirilowii maxim and rhubarb on the level of blood lipids and related pro-inflammatory cytokines during the process of treating atherosclerosis].Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 May;31(5):667-71. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011. PMID: 21812271 Chinese.
-
Oral Presentation Award Winner: LDL-C Reduction in Diabetic Patients after Percutaneous Coronary Intervention: Is There any Difference with Non-diabetic?Eur Cardiol. 2023 Apr 25;18:e19. doi: 10.15420/ecr.2023.18.PO2. eCollection 2023. Eur Cardiol. 2023. PMID: 37405339 Free PMC article. Review. No abstract available.
Cited by
-
Rosuvastatin reduces ischemia-reperfusion injury in patients with acute coronary syndrome treated with percutaneous coronary intervention.Clin Cardiol. 2014 Sep;37(9):530-5. doi: 10.1002/clc.22292. Epub 2014 Aug 25. Clin Cardiol. 2014. PMID: 25156269 Free PMC article. Clinical Trial.
-
Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans.Chronic Dis Transl Med. 2017 Nov 14;4(2):117-126. doi: 10.1016/j.cdtm.2017.09.004. eCollection 2018 Jun. Chronic Dis Transl Med. 2017. PMID: 29988855 Free PMC article.
-
Hypertensive vascular remodeling was inhibited by Xuezhikang through the regulation of Fibulin-3 and MMPs in spontaneously hypertensive rats.Int J Clin Exp Med. 2015 Feb 15;8(2):2118-27. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 25932142 Free PMC article.
-
Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study.Eur J Nutr. 2013 Dec;52(8):1843-52. doi: 10.1007/s00394-012-0486-2. Epub 2012 Dec 25. Eur J Nutr. 2013. PMID: 23266743 Clinical Trial.
-
Exploring the Complementary Role of Traditional Chinese Medicine in Enhancing Percutaneous Coronary Intervention Outcomes: Mechanisms, Benefits, and Future Research Directions.Ther Clin Risk Manag. 2025 Jul 10;21:1069-1083. doi: 10.2147/TCRM.S511630. eCollection 2025. Ther Clin Risk Manag. 2025. PMID: 40666694 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous